These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25888331)

  • 1. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.
    Kavalieris L; O'Sullivan PJ; Suttie JM; Pownall BK; Gilling PJ; Chemasle C; Darling DG
    BMC Urol; 2015 Mar; 15():23. PubMed ID: 25888331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
    Raman JD; Kavalieris L; Konety B; Porten S; Daneshmand S; Lotan Y; Loo R
    J Urol; 2021 Dec; 206(6):1380-1389. PubMed ID: 34348469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
    van Kessel KEM; de Jong JJ; Ziel-van der Made ACJ; Roshani H; Haensel SM; Wolterbeek JH; Boevé ER; Oomens EHGM; van Casteren NJ; Krispin M; Boormans JL; Steyerberg EW; van Criekinge W; Zwarthoff EC
    J Urol; 2020 Jul; 204(1):50-57. PubMed ID: 31985322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis.
    Lough T; Luo Q; Luxmanan C; Anderson A; Suttie J; O'Sullivan P; Darling D
    BMC Urol; 2018 Mar; 18(1):18. PubMed ID: 29523118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients.
    Feifer AH; Steinberg J; Tanguay S; Aprikian AG; Brimo F; Kassouf W
    Urology; 2010 Jun; 75(6):1278-82. PubMed ID: 20138655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma.
    Darling D; Luxmanan C; O'Sullivan P; Lough T; Suttie J
    Adv Ther; 2017 May; 34(5):1087-1096. PubMed ID: 28341930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.
    de Jong JJ; Pijpers OM; van Kessel KEM; Boormans JL; Van Criekinge W; Zwarthoff EC; Lotan Y
    Eur Urol Oncol; 2023 Apr; 6(2):183-189. PubMed ID: 36089502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
    van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
    J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology.
    Odisho AY; Berry AB; Ahmad AE; Cooperberg MR; Carroll PR; Konety BR
    Eur Urol; 2013 May; 63(5):936-40. PubMed ID: 22521093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study.
    Guo RQ; Xiong GY; Yang KW; Zhang L; He SM; Gong YQ; He Q; Li XY; Wang ZC; Bao ZQ; Li XS; Zhang K; Zhou LQ
    Urol Oncol; 2018 Jul; 36(7):342.e15-342.e23. PubMed ID: 29706459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria.
    Abogunrin F; O'Kane HF; Ruddock MW; Stevenson M; Reid CN; O'Sullivan JM; Anderson NH; O'Rourke D; Duggan B; Lamont JV; Boyd RE; Hamilton P; Nambirajan T; Williamson KE
    Cancer; 2012 May; 118(10):2641-50. PubMed ID: 21918968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
    Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
    Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria.
    Loo RK; Lieberman SF; Slezak JM; Landa HM; Mariani AJ; Nicolaisen G; Aspera AM; Jacobsen SJ
    Mayo Clin Proc; 2013 Feb; 88(2):129-38. PubMed ID: 23312369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria.
    Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Kang HW; Kim WT; Lee JY; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
    Urol Oncol; 2019 Jan; 37(1):86-96. PubMed ID: 30446454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.
    Kavalieris L; O'Sullivan P; Frampton C; Guilford P; Darling D; Jacobson E; Suttie J; Raman JD; Shariat SF; Lotan Y
    J Urol; 2017 Jun; 197(6):1419-1426. PubMed ID: 27986532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
    O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
    J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective external validation of a bladder cancer detection model.
    Lotan Y; Svatek RS; Krabbe LM; Xylinas E; Klatte T; Shariat SF
    J Urol; 2014 Nov; 192(5):1343-8. PubMed ID: 24859442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
    Lotan Y; Daneshmand S; Shore N; Black P; Scarpato KR; Patel A; Lough T; Shoskes DA; Raman JD
    J Urol; 2024 Jul; 212(1):41-51. PubMed ID: 38700731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.